Galera Therapeutics, Inc. (GRTX)
Oxford Ledge is still expanding full research coverage of GRTX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Galera Therapeutics develops a nitric oxide synthase inhibitor to treat aggressive forms of breast cancer after shifting focus from radiotherapy side-effect treatments.
SEC filings
- 8-K 3.03; Amendments to articles or bylaws; Financial statements and exhibits 2026-07-13
- 8-K Other material event 2026-07-07
- 8-K Other material event 2026-05-19
- 8-K Amendments to articles or bylaws; Financial statements and exhibits 2026-05-15
- 10-Q Quarterly financial report (unaudited) 2026-05-14
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for GRTX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open GRTX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.